Pasithea Therapeutics Corp. (KTTA) |
|
0.4 -0.03 (-6.93%)
|
03-24 16:00 |
|
Open: |
0.4001 |
Pre. Close: |
0.4298 |
|
High:
|
0.4283 |
Low:
|
0.3911 |
|
Volume:
|
53,536 |
Market Cap:
|
12(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:27:35 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.61 One year: 0.71 |
| Support: |
Support1: 0.39 Support2: 0.32 |
| Resistance: |
Resistance1: 0.52 Resistance2: 0.61 |
| Pivot: |
0.45 |
| Moving Average: |
MA(5): 0.42 MA(20): 0.46
MA(100): 0.72 MA(250): 0.96 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 22.1 %D(3): 26.2 |
| RSI: |
RSI(14): 27.3 |
| 52-week: |
High: 1.53 Low: 0.39 |
| Average Vol(K): |
3-Month: 88 (K) 10-Days: 27 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KTTA ] has closed above bottom band by 3.0%. Bollinger Bands are 34.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.43 - 0.43 |
0.43 - 0.43 |
|
Low:
|
0.39 - 0.39 |
0.39 - 0.39 |
|
Close:
|
0.4 - 0.4 |
0.4 - 0.4 |
|
Company Description |
|
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida. |
Headline News |
Thu, 02 Mar 2023
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to ... - GlobeNewswire
Tue, 24 Jan 2023
PASITHEA THERAPEUTICS CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com
Wed, 18 Jan 2023
Pasithea Therapeutics Signs CMC Development and Manufacturing ... - BioSpace
Mon, 12 Dec 2022
Pasithea Therapeutics Announces Comprehensive Settlement ... - GlobeNewswire
Tue, 06 Dec 2022
Pasithea Therapeutics to Present at Annual Meeting of the Antibody ... - GlobeNewswire
Mon, 28 Nov 2022
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
29 (M) |
|
% Held by Insiders
|
1.846e+007 (%) |
|
% Held by Institutions
|
23.5 (%) |
|
Shares Short
|
170 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-4 |
|
Return on Assets (ttm)
|
481.1 |
|
Return on Equity (ttm)
|
-20.7 |
|
Qtrly Rev. Growth
|
260910 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
52920 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
